{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T10:44:52Z","timestamp":1769251492840,"version":"3.49.0"},"reference-count":34,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:00:00Z","timestamp":1707523200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["PHT-178435"],"award-info":[{"award-number":["PHT-178435"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010564","name":"Academic Medical Organization of Southwestern Ontario","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,6,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>The extent of disease severity remains unclear among CYP2C19 rapid and ultra-rapid metabolizers with refractory symptoms of gastroesophageal reflux disease (GERD) on chronic proton-pump inhibitors (PPIs).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Aims<\/jats:title>\n                  <jats:p>To determine the impact of CYP2C19 metabolizer status in relation to chronic PPI therapy with a focus on the extent of esophageal inflammation, acid exposure, and motor function.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This retrospective study included 54 patients with refractory GERD symptoms who underwent CYP2C19 genotyping for PPI metabolism, esophagogastroduodenoscopy, ambulatory pH study, and high-resolution esophageal manometry. Patients were divided into three groups: normal metabolizer (NM) group, intermediate metabolizer\/poor metabolizer (IM\/PM) group, and rapid metabolizer\/ultra-rapid metabolizer (RM\/UM) group. The Chi-square test was used to analyze categorical variables, and one-way ANOVA for comparing means.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Rapid metabolizer\/ultra-rapid metabolizer (RM\/UM) group more frequently had either Los Angeles grade C or D GERD (7\/19, 36.8% vs 1\/21, 4.8%, P = 0.011) and metaplasia of the esophagus (9\/19, 47.4% vs 2\/21, 9.5%, P = 0.007) when compared to the NM group. RM\/UM group were more frequently offered dilatation for nonobstructive dysphagia (8\/19, 42.1% vs 3\/21, 14.3%, P = 0.049) and more exhibited a hypotensive lower esophageal sphincter (LES) resting pressure compared to the NM group (10\/19, 52.6% vs 4\/21, 19%, P = 0.026). All three groups exhibited comparable DeMeester scores when PPIs were discontinued 72 hours before the ambulatory pH study.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>CYP2C19 RMs and UMs on chronic PPI with refractory GERD symptoms exhibited greater esophageal mucosal inflammation, as observed both endoscopically and histologically, and more were found to have hypotensive LES resting pressures and more were offered esophageal dilatation.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jcag\/gwae005","type":"journal-article","created":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T18:11:37Z","timestamp":1707588697000},"page":"238-245","source":"Crossref","is-referenced-by-count":5,"title":["Impact of CYP2C19 metabolizer status on esophageal mucosal inflammation, acid exposure, and motility among patients on chronic proton-pump inhibitor therapy with refractory symptoms of gastroesophageal reflux disease"],"prefix":"10.1093","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-2287-4458","authenticated-orcid":false,"given":"Cheng-Chun","family":"Tai","sequence":"first","affiliation":[{"name":"Department of Medicine, Schulich School of Medicine & Dentistry, Western University , London, ON N6A 5C1 , Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samantha","family":"Medwid","sequence":"additional","affiliation":[{"name":"Department of Medicine, Schulich School of Medicine & Dentistry, Western University , London, ON N6A 5C1 , Canada"},{"name":"Division of Clinical Pharmacology, Department of Medicine, Schulich School of Medicine and Dentistry, Western University , London, ON N6A 5C1 , Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keith","family":"Mclntosh","sequence":"additional","affiliation":[{"name":"Department of Medicine, Schulich School of Medicine & Dentistry, Western University , London, ON N6A 5C1 , Canada"},{"name":"Division of Gastroenterology, Department of Medicine, Schulich School of Medicine & Dentistry, Western University , London, ON N6A 5C1 , Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nilesh","family":"Chande","sequence":"additional","affiliation":[{"name":"Department of Medicine, Schulich School of Medicine & Dentistry, Western University , London, ON N6A 5C1 , Canada"},{"name":"Division of Gastroenterology, Department of Medicine, Schulich School of Medicine & Dentistry, Western University , London, ON N6A 5C1 , Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard B","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Medicine, Schulich School of Medicine & Dentistry, Western University , London, ON N6A 5C1 , Canada"},{"name":"Division of Clinical Pharmacology, Department of Medicine, Schulich School of Medicine and Dentistry, Western University , London, ON N6A 5C1 , Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"Gregor","sequence":"additional","affiliation":[{"name":"Department of Medicine, Schulich School of Medicine & Dentistry, Western University , London, ON N6A 5C1 , Canada"},{"name":"Division of Gastroenterology, Department of Medicine, Schulich School of Medicine & Dentistry, Western University , London, ON N6A 5C1 , Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2024,2,10]]},"reference":[{"key":"2024060420444344500_CIT0001","first-page":"2128","article-title":"The burden of gastrointestinal and liver diseases, 2006","volume-title":"Am J Gastroenterol.","author":"Shaheen","year":"2006"},{"key":"2024060420444344500_CIT0002","first-page":"S9","article-title":"Acid suppression: optimizing therapy for gastroduodenal ulcer healing, gastroesophageal reflux disease, and stress-related erosive syndrome","volume-title":"Gastroenterology.","author":"Wolfe","year":"2000"},{"key":"2024060420444344500_CIT0003","first-page":"447","article-title":"Proton pump inhibitors: from CYP2C19 pharmacogenetics to precision medicine","volume-title":"Expert Opin Drug Metab Toxicol.","author":"El Rouby","year":"2018"},{"key":"2024060420444344500_CIT0004","first-page":"509","article-title":"Evaluation of CYP2C19 gene polymorphisms in patients with acid peptic disorders treated with esomeprazole","volume-title":"Pharmgenomics Pers Med","author":"Diaz-Ordonez","year":"2021"},{"key":"2024060420444344500_CIT0005","first-page":"175","article-title":"Antiplatelet drug interactions with proton pump inhibitors","volume-title":"Expert Opin Drug Metab Toxicol.","author":"Scott","year":"2014"},{"key":"2024060420444344500_CIT0006","first-page":"1417","article-title":"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2C19 and proton pump inhibitor dosing","volume-title":"Clin Pharmacol Ther.","author":"Lima","year":"2021"},{"key":"2024060420444344500_CIT0007","article-title":"Omeprazole therapy and CYP2C19 genotype","volume-title":"Medical Genetics Summaries","author":"Dean","year":"2012"},{"key":"2024060420444344500_CIT0008","first-page":"716","article-title":"Rapid metabolizer genotype of CYP2C19 is a risk factor of being refractory to proton pump inhibitor therapy for reflux esophagitis","volume-title":"J Gastroenterol Hepatol.","author":"Ichikawa","year":"2016"},{"key":"2024060420444344500_CIT0009","first-page":"27","article-title":"Survey of findings in patients having persistent heartburn on proton pump inhibitor therapy","volume-title":"Dis Esophagus.","author":"Mandaliya","year":"2016"},{"issue":"4","key":"2024060420444344500_CIT0010","first-page":"325","article-title":"Twenty-four-hour pH monitoring of the distal esophagus. A quantitative measure of gastroesophageal reflux","volume":"62","author":"Johnson","year":"1974","journal-title":"Am J Gastroenterol."},{"key":"2024060420444344500_CIT0011","first-page":"doy118","article-title":"Does DeMeester score still define GERD","volume-title":"Dis Esophagus.","author":"Neto","year":"2019"},{"key":"2024060420444344500_CIT0012","first-page":"86","article-title":"Esophageal motility abnormalities in gastroesophageal reflux disease","volume-title":"World J Gastrointest Pharmacol Ther.","author":"Martinucci","year":"2014"},{"key":"2024060420444344500_CIT0013","first-page":"800","article-title":"Interchangeable use of proton pump inhibitors based on relative potency","volume-title":"Clin Gastroenterol Hepatol.","author":"Graham","year":"2018"},{"issue":"1650","key":"2024060420444344500_CIT0014","first-page":"79","article-title":"Addendum: Dexlansoprazole for GERD","volume":"64","year":"2022","journal-title":"Med Lett Drugs Ther."},{"key":"2024060420444344500_CIT0015","first-page":"172","article-title":"Endoscopic assessment of oesophagitis: clinical and functional correlates and further validation of the Los Angeles classification","volume-title":"Gut.","author":"Lundell","year":"1999"},{"key":"2024060420444344500_CIT0016","first-page":"9239074","article-title":"Research on gastroesophageal reflux disease based on dynamic features of ambulatory 24-hour esophageal pH monitoring","volume-title":"Comput Math Methods Med.","author":"Liu","year":"2017"},{"key":"2024060420444344500_CIT0017","volume-title":"Approach to refractory gastroesophageal reflux disease in adults","author":"Fass","year":"2022"},{"key":"2024060420444344500_CIT0018","first-page":"1595","article-title":"Omeprazole 40 mg once a day is equally effective as lansoprazole 30 mg twice a day in symptom control of patients with gastro-oesophageal reflux disease (GERD) who are resistant to conventional-dose lansoprazole therapy-a prospective, randomized, multi-centre study","volume-title":"Aliment Pharmacol Ther.","author":"Fass","year":"2000"},{"key":"2024060420444344500_CIT0019","first-page":"20406223211056719","article-title":"Can acid exposure time replace the DeMeester score in the diagnosis of gastroesophageal reflux-induced cough","volume-title":"Ther Adv Chronic Dis","author":"Zhu","year":"2021"},{"key":"2024060420444344500_CIT0020","first-page":"89","article-title":"Association between CYP2C19*17 alleles and pH probe testing outcomes in children with symptomatic gastroesophageal reflux","volume-title":"J Clin Pharmacol.","author":"Franciosi","year":"2018"},{"key":"2024060420444344500_CIT0021","first-page":"e24361","article-title":"A Study on the correlation between endoscopic findings and symptoms of Gastroesophageal Reflux Disease (GERD)","volume-title":"Cureus","author":"Domakunti","year":"2022"},{"key":"2024060420444344500_CIT0022","first-page":"E342","article-title":"Real-world prevalence of endoscopic findings in patients with gastroesophageal reflux symptoms: a cross-sectional study","volume-title":"Endosc Int Open","author":"Weissman","year":"2022"},{"key":"2024060420444344500_CIT0023","first-page":"661","article-title":"Can symptoms predict endoscopic findings in GERD","volume-title":"Gastrointest Endosc.","author":"Locke","year":"2003"},{"key":"2024060420444344500_CIT0024","first-page":"2060","article-title":"Factors associated with residual gastroesophageal reflux disease symptoms in patients receiving proton pump inhibitor maintenance therapy","volume-title":"World J Gastroenterol.","author":"Kawara","year":"2017"},{"key":"2024060420444344500_CIT0025","first-page":"195","article-title":"CYP2C19*17 gain-of-function polymorphism is associated with peptic ulcer disease","volume-title":"Clin Pharmacol Ther.","author":"Musumba","year":"2013"},{"key":"2024060420444344500_CIT0026","first-page":"517","article-title":"Review article: cellular and molecular mechanisms of NSAID-induced peptic ulcers","volume-title":"Aliment Pharmacol Ther.","author":"Musumba","year":"2009"},{"key":"2024060420444344500_CIT0027","first-page":"357","article-title":"Influence of CYP2C9 genetic variants on gastrointestinal bleeding associated with nonsteroidal anti-inflammatory drugs: a systematic critical review","volume-title":"Pharmacogenet Genomics.","author":"Estany-Gestal","year":"2011"},{"key":"2024060420444344500_CIT0028","first-page":"401","article-title":"Management of the patient with incomplete response to PPI therapy","volume-title":"Best Pract Res Clin Gastroenterol.","author":"Kahrilas","year":"2013"},{"key":"2024060420444344500_CIT0029","first-page":"1192","article-title":"Empiric dilation in non-obstructive dysphagia","volume-title":"Dig Dis Sci.","author":"Olson","year":"2008"},{"key":"2024060420444344500_CIT0030","first-page":"5416","article-title":"Empirical dilation of non-obstructive dysphagia: current understanding and future directions","volume-title":"Dig Dis Sci.","author":"Al Saleh","year":"2022"},{"key":"2024060420444344500_CIT0031","first-page":"19","article-title":"Rapid progressive long esophageal stricture caused by gastroesophageal reflux disease after pylorus-preserving pancreatoduodenectomy","volume-title":"BMC Surg.","author":"Fukaya","year":"2016"},{"key":"2024060420444344500_CIT0032","first-page":"155","article-title":"Lower esophageal sphincter pressure in patients with gastroesophageal reflux diseases and posture and time patterns","volume-title":"Dis Esophagus.","author":"Meining","year":"2004"},{"key":"2024060420444344500_CIT0033","first-page":"241","article-title":"Factors affecting esophageal motility in gastroesophageal reflux disease","volume-title":"Arch Surg.","author":"Chrysos","year":"2003"},{"issue":"4","key":"2024060420444344500_CIT0034","first-page":"769","article-title":"Circadian esophageal motor function in patients with gastroesophageal reflux disease","volume":"108","author":"Stein","year":"1990","journal-title":"Surgery."}],"container-title":["Journal of the Canadian Association of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcag\/article-pdf\/7\/3\/238\/58083599\/gwae005.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcag\/article-pdf\/7\/3\/238\/58083599\/gwae005.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,5]],"date-time":"2024-06-05T01:24:26Z","timestamp":1717550666000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcag\/article\/7\/3\/238\/7606271"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,10]]},"references-count":34,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024,2,10]]},"published-print":{"date-parts":[[2024,6,4]]}},"URL":"https:\/\/doi.org\/10.1093\/jcag\/gwae005","relation":{},"ISSN":["2515-2084","2515-2092"],"issn-type":[{"value":"2515-2084","type":"print"},{"value":"2515-2092","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,6,1]]},"published":{"date-parts":[[2024,2,10]]}}}